Yousif Capital Management LLC Has $3.72 Million Holdings in Medpace Holdings, Inc. $MEDP

Yousif Capital Management LLC decreased its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 11.9% in the 3rd quarter, HoldingsChannel reports. The fund owned 7,226 shares of the company’s stock after selling 979 shares during the period. Yousif Capital Management LLC’s holdings in Medpace were worth $3,715,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Norges Bank acquired a new stake in Medpace in the 2nd quarter valued at $66,597,000. Clarkston Capital Partners LLC bought a new position in shares of Medpace in the second quarter valued at $40,569,000. Mawer Investment Management Ltd. grew its holdings in shares of Medpace by 17.4% during the second quarter. Mawer Investment Management Ltd. now owns 817,432 shares of the company’s stock valued at $256,559,000 after buying an additional 121,213 shares during the last quarter. Bares Capital Management Inc. increased its position in shares of Medpace by 319.2% during the second quarter. Bares Capital Management Inc. now owns 157,084 shares of the company’s stock worth $49,302,000 after acquiring an additional 119,608 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of Medpace by 79.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 265,270 shares of the company’s stock worth $83,258,000 after acquiring an additional 117,301 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors.

Insider Activity at Medpace

In other news, President Jesse J. Geiger sold 21,503 shares of the stock in a transaction that occurred on Wednesday, November 5th. The shares were sold at an average price of $595.66, for a total transaction of $12,808,476.98. Following the completion of the transaction, the president directly owned 15,000 shares of the company’s stock, valued at $8,934,900. This represents a 58.91% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Susan E. Burwig sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the sale, the vice president owned 27,500 shares of the company’s stock, valued at approximately $16,751,625. The trade was a 42.11% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 387,925 shares of company stock worth $233,386,647. 20.30% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on MEDP shares. Rothschild Redb downgraded Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, September 3rd. Wall Street Zen cut Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, December 20th. Weiss Ratings reiterated a “buy (b)” rating on shares of Medpace in a report on Friday, October 31st. Jefferies Financial Group raised their price objective on Medpace from $400.00 to $450.00 and gave the company a “hold” rating in a research note on Tuesday, September 9th. Finally, Rothschild & Co Redburn downgraded shares of Medpace from a “buy” rating to a “neutral” rating and lifted their price objective for the stock from $342.00 to $474.00 in a report on Wednesday, September 3rd. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, ten have assigned a Hold rating and four have assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $490.82.

Medpace Trading Down 0.8%

Shares of Medpace stock opened at $567.56 on Friday. The business’s fifty day simple moving average is $579.62 and its 200 day simple moving average is $480.17. Medpace Holdings, Inc. has a 12 month low of $250.05 and a 12 month high of $626.26. The firm has a market capitalization of $15.99 billion, a P/E ratio of 39.69, a price-to-earnings-growth ratio of 2.16 and a beta of 1.43.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.50 by $0.36. The firm had revenue of $659.90 million during the quarter, compared to the consensus estimate of $640.49 million. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The business’s revenue for the quarter was up 23.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.01 EPS. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. Analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.